Indeed, when breast cancer samples were classified based on the activation status of ERK and RAR signaling, patients with low RAR signaling activity and high ERK signaling activity showed the worst prognosis in terms of overall survival and relapse-free survival (Figure 6). This evidence concerns the gene RARA and breast cancer.